Analysis of Clinical Effect of Concurrent Chemo/radiotherapy in the Treatment of Advanced Cervical Cancer

Rebaz Mohammed, Christopher Halpin

Abstract


The study aimed to analyze the efficacy and adverse effects of concurrent chemo/radiotherapy in the treatment of advanced cervical cancer, and the efficacy and safety of concurrent chemo/radiotherapy were evaluated to standardize the treatment. First of all, retrospective analysis was carried out, and 30 cases of advanced cervical cancer treated in hospitals from 2013 to 2018 were included in the study. 30 cases of concurrent chemo/radiotherapy were included in the synchronous group, and 30 cases of radical radiotherapy alone were included in the radiotherapy group. The results showed that the CR rate and remission rate in the synchronous group were 43.3% and 93.3%, which were higher than those in the radiotherapy group (26.7% and 80.0%). The 3-year survival rate of the synchronous group was 80.0%, which was higher than that of the radiotherapy group, with a statistically significant difference (P<0.05). There was no significant difference in 3-year all-cause mortality, 5-year survival and 5-year all-cause mortality between the two groups. The tumor-free survival time in the synchronous group was (24.4±8.2) months, which was higher than that in the radiotherapy group (17.0±8.5) months, and the difference was statistically significant (P<0.05). Therefore, compared with radiotherapy alone, concurrent chemo/ radiotherapy in the treatment of advanced cervical cancer can improve the 3-year survival rate and prolong the tumor-free survival time. However, it did not increase 5-year survival rate, and bone marrow suppression and gastrointestinal reactions were increased. 


Keywords


Cervical cancer; Concurrent chemo/radiotherapy; Radical radiotherapy alone; Survival rate

Full Text:

PDF

References


Gao Ting, LI Chao, Liang Zn, et al. International comparison of cancer prevalence in China [J]. Chinese cancer,2016,25(6):409-411.

Wu Bing, Zhang Chongyi, Li Mingfen, et al. A study on the correlation between human papillomavirus infection and cervical lesions [J]. Chin J nosocomial infectious science,2013,23(10): 2377-2378.

Chen Mingxiao. Clinical control study of cisplatin concurrent chemoradiotherapy and radiotherapy alone in the treatment of advanced Cervical Cancer [J]. Contemporary medicine,2016,22(2):118-119.

Li Nanxin. Clinical comparison of concurrent chemoradiotherapy and radiotherapy alone in the treatment of advanced cervical cancer [J]. Contemporary medicine,2013,19(26):93-94.

Dai Yifei, Tian Ronghua. Significance of TCT combined with HPV detection in cervical lesion screening [J]. Chinese general practice,2012,10(10):1556-1559.

Gan Zuhuan, Gan Langge, Tan Yi. Advances in the application of concurrent chemoradiotherapy in advanced cervical cancer [J]. Chinese new clinical medicine,2014,7(4):371-373.

Zhang Lei, TANG Jie, Zhang Juanjuan. Meta-analysis of concurrent chemoradiotherapy and radiotherapy alone in the treatment of locally advanced cervical cancer [J]. Chinese journal of clinicians,2014,8(15): 2827-2832.

Ao Meihong, LI Longyu. Meta-analysis of effect of consolidation chemotherapy on prognosis of cervical cancer after concurrent chemoradiotherapy [J]. Advances in modern obstetrics and gynecology,2015,24(7):528-530.

Jin Fenglan, MA Ning, Yang Lei, et al. Meta-analysis of therapeutic effect of different single drug chemotherapy regimens with concurrent chemoradiotherapy for cervical Cancer [J]. Maternal and child health care in China,2012,27(12):1911-1914.

Gao Ping, Guan Xiaoqian, Gao Yajie. (in Chinese) Comparison of efficacy and safety between concurrent chemoradiotherapy with nedaplatin and concurrent chemoradiotherapy with cisplatin + 5-fluorouracil in patients with advanced uterine cervical cancer [J]. China maternal and child health care,2013,28(22):3675-3677.




DOI: http://dx.doi.org/10.30564/amor.v5i6.259

Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Rebaz Mohammed, Christopher Halpin

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.